$JAZZJazz Pharmaceuticals plc

📅 Upcoming

🕒 Recent(90d)

News

• How Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban
  Virtually all of the 175,000 public comments on a 2022 FDA proposal to ban menthol cigarettes were form letters, most echoing tobacco industry talking points.
  stat · 9d ago
• An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
  Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
  biopharma_dive · 12d ago
• Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
  Iambic Therapeutics is maintaining the momentum generated by its recent mega round and Big Pharma partnerships by gearing up to go public.
  fiercebiotech · 12d ago
• Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
  MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…
  fiercebiotech · 20d ago
• Beyond China: Five other overseas destinations for biopharma dollars
  As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.
  biospace · 25d ago
• UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy
  Plus, news about Regeneron, Novocure, Jazz's Ziihera, BioMarin, Ascendis, AstraZeneca, Hutchmed and TScan Therapeutics. Another road bump for Tavneos: The Medicines and Healthcare products Regulato…
  endpoints · 1mo ago
• Roche nabs expanded FDA approval for diagnostic tied to Jazz’s cancer drug
  Roche has been given an extended clearance by the FDA for its tests that can find patients eligible to use Jazz Pharmaceuticals’ oncology med Ziihera.
  fiercebiotech · 1mo ago
• Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
  Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
  biospace · 1mo ago
• New Jazz cancer drug approval could drive blockbuster sales
  Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
  biopharma_dive · 1mo ago
• FDA approves Jazz's Ziihera in frontline gastric cancer
  Jazz Pharmaceuticals’ bispecific antibody Ziihera won a label expansion to treat certain patients with gastric cancer. It’s the first time Ziihera will be marketed to newly diagnosed patients, foll…
  endpoints · 1mo ago